Paramyotonia congenita of Von Eulenburg

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:684OMIM:168300G71.1
Who is this for?
Show terms as
7Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Paramyotonia congenita of Von Eulenburg (PMC) is a rare inherited skeletal muscle disorder belonging to the group of non-dystrophic myotonias caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4 in skeletal muscle. The condition is characterized by myotonia (difficulty relaxing muscles after voluntary contraction) that is paradoxically worsened by repeated muscle use — hence the term 'paramyotonia,' which distinguishes it from classical myotonia where repeated contractions typically improve stiffness. A hallmark feature of PMC is that symptoms are prominently triggered or aggravated by cold exposure. The disease primarily affects skeletal muscles, with the face, hands, and forearms being most commonly involved. Patients may experience muscle stiffness, difficulty opening the eyes or releasing grip in cold environments, and episodes of muscle weakness that can follow prolonged myotonia or cold exposure. Symptoms are typically present from birth or early infancy and remain relatively stable throughout life, though they do not usually worsen progressively. During cold-induced episodes, patients may develop flaccid weakness lasting minutes to hours. The severity of symptoms varies among affected individuals, even within the same family. Electromyography (EMG) typically demonstrates myotonic discharges, and genetic testing of the SCN4A gene confirms the diagnosis. There is no cure for paramyotonia congenita, but treatment focuses on symptom management. Sodium channel blockers such as mexiletine are the primary pharmacological treatment and can effectively reduce myotonia in many patients. Avoidance of cold exposure and careful management of triggers are important non-pharmacological strategies. Other medications that have been used include lamotrigine, flecainide, and acetazolamide, though evidence is more limited. The condition does not typically affect life expectancy, and most patients maintain a good quality of life with appropriate management.

Also known as:

Clinical phenotype terms— hover any for plain English:

Neonatal inspiratory stridorHP:0004875Percussion myotoniaHP:0010548Paradoxical myotoniaHP:0011809Facial muscle hypertrophyHP:0012892Handgrip myotoniaHP:0012899Myotonia of the faceHP:0012900Myotonia of the jawHP:0012901Myotonia of the upper limbHP:0012903Cold-sensitive myotoniaHP:0012904Cold paresisHP:0031372Periodic hypokalemic paresisHP:0008153Abnormal circulating potassium concentrationHP:0011042
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Paramyotonia congenita of Von Eulenburg.

View clinical trials →

No actively recruiting trials found for Paramyotonia congenita of Von Eulenburg at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Paramyotonia congenita of Von Eulenburg community →

Specialists

7 foundView all specialists →
SM
Savine Vicart, MD
Specialist
PI on 1 active trial
BP
Bertrand Fontaine, MD, PhD
Specialist
PI on 1 active trial
WM
William D Arnold, MD
Specialist
PI on 2 active trials1 Paramyotonia congenita of Von Eulenburg publication
RM
Richard Barohn, MD
COLUMBIA, MO
Specialist
PI on 3 active trials
PP
Prof. dr. BGM van Engelen, MD, PhD
Specialist
PI on 1 active trial
PP
Prof. dr. GJ van der Wilt, PhD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Paramyotonia congenita of Von Eulenburg.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Paramyotonia congenita of Von EulenburgForum →

No community posts yet. Be the first to share your experience with Paramyotonia congenita of Von Eulenburg.

Start the conversation →

Latest news about Paramyotonia congenita of Von Eulenburg

No recent news articles for Paramyotonia congenita of Von Eulenburg.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Paramyotonia congenita of Von Eulenburg

What is Paramyotonia congenita of Von Eulenburg?

Paramyotonia congenita of Von Eulenburg (PMC) is a rare inherited skeletal muscle disorder belonging to the group of non-dystrophic myotonias caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4 in skeletal muscle. The condition is characterized by myotonia (difficulty relaxing muscles after voluntary contraction) that is paradoxically worsened by repeated muscle use — hence the term 'paramyotonia,' which distinguishes it from classical myotonia where repeated contractions typically improve stiffness. A hallmark feature of PMC is that symptoms are promin

How is Paramyotonia congenita of Von Eulenburg inherited?

Paramyotonia congenita of Von Eulenburg follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Paramyotonia congenita of Von Eulenburg typically begin?

Typical onset of Paramyotonia congenita of Von Eulenburg is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Paramyotonia congenita of Von Eulenburg?

7 specialists and care centers treating Paramyotonia congenita of Von Eulenburg are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.